News Novartis' pelacarsen fail raises questions for other drugs The data from Novartis' disappointing cardiovascular outcomes trial with Lp(a)-targeting pelacarsen have been revealed, leaving cardiologists puzzled.
News ACC25: Positive results with Lilly's Lp(a)-lowering drug Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.
News AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.